Flag of the European Union EU Clinical Trials Register Help

Clinical trials for - Crohn’s Disease AND HIV Infection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    613 result(s) found for: - Crohn’s Disease AND HIV Infection. Displaying page 11 of 31.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2009-017032-41 Sponsor Protocol Number: AI424-402 Start Date*: 2011-08-01
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and...
    Medical condition: HIV-1 infected subjects who are virologically suppressed on a regimen of 2 NRTIs plus any 3rd agent, but experience safety and/or tolerability issues to this regimen.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001749-25 Sponsor Protocol Number: 111474 Start Date*: 2008-06-18
    Sponsor Name:Mater Misericordiae University Hospital
    Full Title: An open label safety study of fosamprenavir/ritonavir (FPV/rtv (Telzir)) administered to HIV/HCV co-infected patients over 96 weeks
    Medical condition: Antiretroviral - Naive HIV-1 Infected Adults and Antiretroviral Experienced HIV-1 Infected Adults
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008922 Chronic infection with HIV LLT
    Population Age: Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002694-13 Sponsor Protocol Number: COMBOKA-07 Start Date*: 2009-06-18
    Sponsor Name:Fundación Biomédica del CHUVI
    Full Title: Estudio piloto, fase IV para analizar la seguridad de los combos Truvada vs Kivexa como parte de un TARGA basado en Kaletra. Estudio COMBOKA
    Medical condition: Paciente infectado por el VIH sin tratamiento antirretroviral previo
    Disease: Version SOC Term Classification Code Term Level
    9 10020162 HIV infection CDC Group I LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003172-32 Sponsor Protocol Number: MASH Start Date*: 2018-05-23
    Sponsor Name:Imperial College London
    Full Title: Maraviroc Add-On Therapy for Steatohepatitis in HIV – The MASH Study
    Medical condition: Non alcoholic steatohepatitis (NASH) in patients with HIV mono-infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003160-32 Sponsor Protocol Number: TMC125-C216 Start Date*: 2005-12-13
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) ES (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002077-35 Sponsor Protocol Number: 111634 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled study in South Africa to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine administered as a 3-dose (6,...
    Medical condition: 3- or 2-dose primary vaccination against Streptococcus pneumoniae together with a 3-dose primary vaccination against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b di...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    14.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002359-18 Sponsor Protocol Number: PEDVAC Start Date*: 2008-04-23
    Sponsor Name:Swedish Institute for Infectious Disease Control
    Full Title: DNA vaccination in HIV-vertically infected children
    Medical condition: Pazienti con infezione verticale da HIV di eta' compresa tra 4 -16 anni di ambo i sessi.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053500 Human immunodeficiency virus transmission LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000816-24 Sponsor Protocol Number: FRAN-03-001 Start Date*: 2004-10-28
    Sponsor Name:Abbott France
    Full Title: A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antir...
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    7.0 10020192 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003629-86 Sponsor Protocol Number: ING114915 Start Date*: 2012-01-27
    Sponsor Name:Viiv Healthcare
    Full Title: A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each admini...
    Medical condition: HIV-1 infection in ART-naïve subjects.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005135-10 Sponsor Protocol Number: 2005-151 Start Date*: 2006-01-19
    Sponsor Name:Jeppe Hagstrup Christensen
    Full Title: Omacor; omega-3-acid ethyl ester 90 (N-3 PUFA) and risk faktors in HIV infected patients treated with HAART with special focus on lipids
    Medical condition: Several investigations show that HIV infected patients have a higher risk for development of heart disease if treated with HAART. The investigation will evaluate the effect of fish oil on blood ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005078-40 Sponsor Protocol Number: TESEC-05 Start Date*: 2016-06-03
    Sponsor Name:Statens Serum Institut
    Full Title: A Phase III trial in subjects suspected to have tuberculosis, comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomised splitbody s...
    Medical condition: Children (28 days–4 years old) with suspected Mycobacterium tuberculosis infection Participants between 5–65 years old who attended the TB clinic due to suspicion of TB disease (HIV positive and HI...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002849-40 Sponsor Protocol Number: DermHivImm Start Date*: 2006-03-29
    Sponsor Name:Swedish Institute for Infectious Disease Control
    Full Title: Active immunotherapy against HIV during highly active anti-retroviral therapy followed by repeated treatment interruptions, VAC 09.
    Medical condition: Treatment of HIV infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020983-39 Sponsor Protocol Number: ING114467 Start Date*: 2010-12-30
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks ...
    Medical condition: HIV-1 infected antiretroviral therapy naive adult subjects.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) GB (Completed) HU (Completed) DK (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000748-14 Sponsor Protocol Number: M06-802 Start Date*: 2006-08-14
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib...
    Medical condition: Antiretroviral experienced, HIV-1 Infection. Adequate ICD classification code not available.
    Disease: Version SOC Term Classification Code Term Level
    9.0 10020192 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003984-23 Sponsor Protocol Number: BOC-HIV Start Date*: 2013-04-19
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: A phase III open label study to evaluate safety and efficacy of Boceprevir-response guided therapy in controlled HIV patients with chronic hepatitis C genotype 1 infection who failed previously to ...
    Medical condition: HCV and HIV seropositive coinfection
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10065949 HCV coinfection LLT
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004524-65 Sponsor Protocol Number: Inf.Q002 Start Date*: 2015-11-30
    Sponsor Name:Department of Infectious Diseases
    Full Title: Efficacy of nonavalent vaccine against human papilloma virus (HPV ) in HIV infected sexually active men who have sex with men (MSM)
    Medical condition: The purpose of the study is to investigate the efficacy of a new nonavalent HPV vaccine in sexually active HIV-infected MSM.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10063001 Human papilloma virus infection LLT
    18.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001228-32 Sponsor Protocol Number: COV002 Start Date*: 2020-05-04
    Sponsor Name:CTRG
    Full Title: A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004195-19 Sponsor Protocol Number: CREPATS10 Start Date*: 2020-07-07
    Sponsor Name:Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS)
    Full Title: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma vire...
    Medical condition: HIV disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020160 HIV disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015904-24 Sponsor Protocol Number: UKB-2009-MED-I-JKR-01 Start Date*: 2010-10-20
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection i...
    Medical condition: HIV disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004306-50 Sponsor Protocol Number: A4001050 Start Date*: 2007-04-23
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 HIV-1 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) BE (Completed) CZ (Completed) DE (Completed) PT (Completed) ES (Completed) NL (Completed) AT (Completed) GR (Completed) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Aug 07 13:24:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA